S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
SHOCKING Crypto Leak… (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
SHOCKING Crypto Leak… (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
SHOCKING Crypto Leak… (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
1970’s computer coder issues shocking A.I. warning (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
SHOCKING Crypto Leak… (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free FREQ Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.28
▼
$0.32
50-Day Range
$0.22
▼
$14.98
52-Week Range
$0.18
▼
$16.00
Volume
309,164 shs
Average Volume
822,537 shs
Market Capitalization
$10.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial Media
FREQ stock logo

About Frequency Therapeutics Stock (NASDAQ:FREQ)

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

FREQ Stock News Headlines

April 18, 2024 | apnews.com
Best red light therapy devices for getting an at-home glow-up
April 15, 2024 | tmcnet.com
Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
April 12, 2024 | msn.com
We tried it: Sound therapy, via app
April 12, 2024 | finance.yahoo.com
Egg Allergy Drug Pipeline Research 2024 Featuring Aimmune Therapeutics, DBV Technologies, and ASIT Biotech
April 11, 2024 | finance.yahoo.com
Adaptive Sound Technologies, Inc. Launches Sound+Therapy, Their Latest And Most Effective Science-Backed Sleep Sound Machine
April 9, 2024 | msn.com
Research shows art therapy brings benefits for mental health
April 8, 2024 | msn.com
Breakthrough in Ultrasound Therapy Shows Cognitive Improvement in Alzheimer's without Targeting Plaques
April 18, 2024 | TradeSmith (Ad)
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
April 8, 2024 | msn.com
Ultra-processed foods linked to higher glaucoma risk, study warns
April 8, 2024 | msn.com
Menopause: Does Menopausal Hormone Therapy or MHT help to manage symptoms?
April 4, 2024 | finance.yahoo.com
Partner Therapeutics' Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
April 2, 2024 | msn.com
Q&A: How do you know when you're done with therapy?
April 2, 2024 | msn.com
Ultrasound therapy shows promise as a treatment for Alzheimer's disease
April 2, 2024 | forbes.com
GLP-1s Vs. Gene Therapy: The New Drugs Making Waves In Self-Insurance
March 29, 2024 | msn.com
How Physical Therapy Can Help You on Your Road to Recovery After Mastectomy
March 27, 2024 | msn.com
Exploring the impact of pancreatic enzyme therapy in pediatric pancreatitis: A leap toward personalized medicine
March 25, 2024 | marketwatch.com
Stocks to Watch: Stoke Therapeutics, Westport Fuel Systems, Ampco-Pittsburgh
March 25, 2024 | marketwatch.com
Stoke Therapeutics Shares Rise 80%, Co. Reports Data From Dravet Syndrome Study
March 25, 2024 | msn.com
Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why
March 22, 2024 | markets.businessinsider.com
Buy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market Potential
March 22, 2024 | finanznachrichten.de
IRLAB Therapeutics: IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam
March 20, 2024 | finance.yahoo.com
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
March 18, 2024 | markets.businessinsider.com
Bestqool Unveils Comprehensive Guide to Optimize Red Light Therapy Dosage for Enhanced Health Benefits
March 17, 2024 | finanznachrichten.de
Heron Therapeutics, Inc.: Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
March 17, 2024 | msn.com
Going for UV light therapy for acne, eczema, vitiligo? Know which technique works for you
March 14, 2024 | forbes.com
The Apollo Wearable Review: Get Touch Therapy On Your Wrist
See More Headlines
Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FREQ
CUSIP
N/A
CIK
1703647
Web
www.frequencytx.com
Phone
781-315-4600
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,580,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-107.67%
Return on Assets
-61.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.81
Quick Ratio
5.81

Sales & Book Value

Annual Sales
$14.07 million
Price / Sales
0.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.96 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
36,520,000
Free Float
30,385,000
Market Cap
$10.94 million
Optionable
Not Optionable
Beta
0.84
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. David L. Lucchino (Age 53)
    Co-Founder, President, CEO & Director
    Comp: $1.02M
  • Mr. Richard J. Mitrano (Age 52)
    Vice President of Finance & Operations
  • Mr. James P. Abely
    Associate General Counsel & Secretary
  • Dr. John L. LaMattina Ph.D. (Age 73)
    Senior Advisor & Member of PCA Regenerative Medicine Advisory Board

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

FREQ Stock Analysis - Frequently Asked Questions

Should I buy or sell Frequency Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings or view top-rated stocks.

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its earnings results on Monday, November, 15th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.16.

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?

Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

This page (NASDAQ:FREQ) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
The “Perfect Storm” for Gold
Gold Safe Exchange
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Top 5 AI Stocks to Buy for 2024
Market Moving Trends